# Microbial Fermentation Technology Market

> Microbial Fermentation Technology Market Research Report: Size, Share, Trend Analysis By Class (Antibiotics (Penicillin, Streptomycin, Tetracycline, Others), Hormones and Growth Factors (Insulin, Human Growth Hormone (HGH), Erythropoietin (EPO), Anticancer Agents (Doxorubicin, Daunorubicin, Others), Immunosuppressants, Others), by End-User (Pharmaceutical Companies, Contract Research Organizations (CROs) and CDMOs, Research Organizations) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 5.94%
- **2025:** USD 39.95 Billion
- **2035:** USD 70.92 Billion
- **Key Players:** Thermo Fisher Scientific, Sartorius AG, Danaher (Cytiva), Merck KGaA, Lonza Group, Novonesis, Eppendorf SE, ABEC Inc.

**Report ID:** MRFR/HC/20277-CR · **Pages:** 237 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/microbial-fermentation-technology-market-21875

---

## Market Summary

According to Market Research Future analysis, the Microbial Fermentation Technology Market was estimated at 37.5 USD Billion in 2024. The microbial fermentation technology industry is projected to grow from 40.57 USD Billion in 2025 to 89.25 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 8.2% during the forecast period 2025 - 2035. North America led the market with over 50% share, generating around USD 18.75 billion in revenue.
 
Growing demand for biopharmaceuticals, vaccines, and sustainable bio-based production is accelerating microbial fermentation technology adoption. Increasing antibiotic resistance and rising need for cost-efficient biologics further strengthen market expansion across healthcare, food, and industrial biotechnology sectors globally.
 
WHO reports over 10.6 million TB cases (2023) and rising antimicrobial resistance affecting 1.27 million deaths annually (IHME). UNICEF supports vaccination for 45%+ of global children annually, driving biologics demand. Gavi enables immunization for over 1 billion children since inception, boosting fermentation-based vaccine production.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Biologics pipeline expansion | +1.4 | Global | Long-term (≥4 yr) | [10] |
| Domestic biomanufacturing incentives | +1.1 | US, EU, India, China | Medium-term (2–4 yr) | [1][8] |
| AI-driven strain engineering | +0.9 | North America, Europe | Medium-term (2–4 yr) | [3] |
| Alternative protein commercialisation | +0.8 | APAC, Europe | Long-term (≥4 yr) | [7] |
| Bio-based chemical substitution mandates | +0.7 | Europe, Japan | Long-term (≥4 yr) | [11] |
| Single-use and modular facility adoption | +0.6 | Global | Short-term (≤2 yr) | [12] |
| Antimicrobial resistance stockpiling programs | +0.4 | US, EU, MEA | Short-term (≤2 yr) | [13] |

### Biologics Pipeline Expansion Anchors Baseline Demand

Approximately 42% of the more than 1,300 biologics candidates in ongoing clinical development rely on microbial expression systems for either the active molecule or a crucial intermediary [[10]](https://bio.org). The Microbial Fermentation Technology Market tracks regulatory throughput more closely than GDP since approvals directly translate into multi-year vessel bookings. In 2024, the FDA approved 17 applications for innovative biologics licenses, each of which secured 8,000 to 40,000 liters of reserved or dedicated capacity for ten years.

### Sovereign Biomanufacturing Incentives Redirect Capital

With the support of approximately USD 2 billion in interagency commitments, Washington's Executive Order on biotechnology set a goal to provide at least 30% of the US chemical needs via biological pathways within 20 years [[1]](https://energy.gov/eere/bioenergy). 35 authorized projects received INR 6,940 crore from India's production-linked incentive scheme for fermentation-based bulk pharmaceuticals; the majority of these projects were commissioned between 2025 and 2028 [[8]](https://pharmaceuticals.gov.in). Projects that would otherwise fail internal hurdle rates are advanced by subsidized capacity, which also lowers the effective cost floor.

### AI Strain Engineering Compresses Development Economics

Machine-learning models trained on multi-omics datasets now propose viable pathway edits in weeks. One published industrial programme reported a 41% titre improvement across four design-build-test cycles, against an eight-cycle historical norm [[3]](https://nap.nationalacademies.org). Shorter cycles reduce the capital tied up in unproductive pilot runs and make marginal molecules economically viable, widening the addressable application set.

### Bio-Based Substitution Rules Create Guaranteed Offtake

Europe's Single-Use Plastics Directive and the associated packaging regulation require rising bio-content thresholds through 2030, which has already triggered long-term PLA and PHA supply agreements [[11]](https://ec.europa.eu). Japan's Green Growth Strategy commits JPY 2 trillion across decarbonisation funds, with bio-manufactured chemicals named as a priority stream. Mandated demand removes the volume risk that historically deterred lenders from funding large fermentation assets.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital intensity of GMP capacity | −0.9 | Global | Long-term (≥4 yr) | [12] |
| Downstream purification cost burden | −0.7 | Global | Medium-term (2–4 yr) | [14] |
| Antibiotic price erosion and generic pressure | −0.6 | India, China, Europe | Short-term (≤2 yr) | [6] |
| Skilled bioprocess workforce shortage | −0.5 | US, EU, MEA | Medium-term (2–4 yr) | [15] |
| Feedstock and utility cost volatility | −0.4 | Europe, South America | Short-term (≤2 yr) | [16] |

### Capital Intensity Keeps New Entrants Out

It takes 40 to 54 months from groundbreaking to product delivery for a complying 50,000-liter microbiological facility, which costs between USD 280 million and USD 450 million [[12]](https://ispe.org). Few precision-fermentation firms are able to provide investment-grade offtake, which is necessary for financing at those tenors. Approximately one-third of publicly declared 2022 projects remain unbuilt as a result of the ongoing discrepancy between announced projects and commissioned tonnage.

### Downstream Processing Consumes the Margin

For microbially generated proteins, recovery and purification normally account for 55% to 80% of the entire production cost; in just ten years, this ratio has hardly changed [[14]](https://nature.com/nbt). As a result, once separation trains reach saturation, upstream titre gains provide declining returns. A second capital round is often required when facilities retrofitted for continuous upstream operation find that their downstream suites become the binding restriction.

### Workforce Scarcity Delays Commissioning

Industry surveys place the global shortfall of qualified bioprocess engineers and QA specialists near 24,000 roles, concentrated in the US Northeast, Ireland, and the Gulf [[15]](https://niimbl.force.com). Vacancies extend validation timelines and inflate wage bills at precisely the sites carrying the heaviest depreciation. Training pipelines through NIIMBL and comparable European consortia are expanding, but graduate volumes lag demand by several years.

## Opportunities

## Microbial Fermentation Technology Market Opportunities

### Continuous Manufacturing Retrofits

Converting existing fed-batch suites to intensified or perfusion operation costs a fraction of greenfield construction while lifting output per square metre substantially. Regulators have signalled support, with the FDA's continuous manufacturing guidance now covering biologics workflows. Vendors selling retrofit skids and control layers into the installed base capture recurring revenue without carrying facility risk, a model well suited to the Microbial Fermentation Technology Market.

### Emerging-Market Capacity Localisation

Brazil, Indonesia, Saudi Arabia, and Nigeria have all published biomanufacturing localisation targets tied to health-security objectives. Saudi Arabia's Vision 2030 biotech strategy allocates funding for domestic vaccine and enzyme production, with the first commercial-scale sites targeted for 2028 [[17]](https://misa.gov.sa). Equipment suppliers that bundle training and validation services alongside hardware win disproportionately in these markets, where technical absorption capacity rather than capital is the true constraint.

### Process Data Monetisation and Outcome-Based Contracts

Modern fermentation bioreactor systems generate terabytes of batch telemetry that most operators discard after release testing. Vendors are beginning to license benchmarking analytics back to customers, and a handful now price on achieved titre rather than hardware delivered. Recurring analytics revenue carries software-like margins and deepens switching costs, reshaping how value accrues within the Microbial Fermentation Technology Market.

### Cell-Free and Consortia Platforms

Cell-free enzymatic systems sidestep cellular maintenance burden and toxicity limits, expanding at a 12.6% CAGR from a small base. Engineered synthetic consortia, growing at 14.0% annually, allow division of metabolic labour across strains for pathways too long for a single host. Both remain pre-scale, but early licensing positions are cheap relative to the option value they carry.

### Circular Feedstock Integration

Agricultural residue, CO₂, and food-industry side streams are becoming viable fermentation inputs as pretreatment costs fall. Brazilian sugarcane operators already co-locate fermentation assets with mills, cutting feedstock logistics to near zero. Carbon-intensity scoring under EU and Californian fuel rules turns that integration into a monetisable premium rather than a cost-saving footnote.

## Future Outlook

## Microbial Fermentation Technology Market Future Outlook

### Autonomous Bioprocessing Becomes Standard

Closed-loop control using soft sensors and Raman spectroscopy will move from pilot suites to routine GMP operation within the decade. Facilities running model-predictive control already report batch-failure reductions near 30% and tighter critical quality attribute distributions [[3]](https://nap.nationalacademies.org). Autonomy reshapes labour economics across the Microbial Fermentation Technology Market, shifting headcount from operators to data engineers and easing the workforce constraint identified in Section 5.

### Platform Economics Displace Product Economics

Ownership of validated host strains, expression cassettes, and regulatory precedent is becoming more valuable than owning steel. Licensing a proven chassis with an existing drug master file removes 12 to 24 months from a customer's timeline, and vendors are pricing accordingly. Expect royalty and milestone structures to account for a rising share of supplier revenue by 2030.

### Feedstock Decarbonisation and Carbon Accounting

The IEA projects bioenergy and bio-based materials demand rising materially under stated-policy scenarios, tightening competition for sustainable carbon [[16]](https://iea.org). Fermentation operators will need verified feedstock chains to sell into Europe and California at premium prices. Gas fermentation on industrial off-gas offers a hedge, with several commercial ethanol-from-steel-mill facilities now operating continuously.

### Consolidation Around Validated Capacity

Scarcity of commissioned, inspected, multi-product fermentation suites will make them acquisition targets rather than organic build decisions. Between 2026 and 2032, expect strategic buyers to pay premiums for assets with clean regulatory histories over those with newer equipment. Consolidation will lift concentration in the Microbial Fermentation Technology Market without eliminating the long tail of regional specialists.

## Segment Insights

## Microbial Fermentation Technology Market Segmentation

Segment structure in the Microbial Fermentation Technology Market mirrors the Mordor taxonomy across application, microorganism type, mode of fermentation, fermenter capacity, and end user. One calibrated metric is disclosed per segment row.

### By Application

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Antibiotics | 30.7% share | Volume base and AMR stockpiling |
| Monoclonal Antibodies | USD 8.59 Billion | Oncology and autoimmune pipeline depth |
| Recombinant Proteins & Enzymes | 16.8% share | Detergent, textile and food processing demand |
| Amino Acids & Organic Acids | USD 4.95 Billion | Animal nutrition and bioplastic precursors |
| Probiotics & Alternative Proteins | 11.9% CAGR | Consumer health and dairy substitution |
| Cell-Free Enzymatic Systems | 12.6% CAGR | Toxic-pathway and rapid-prototyping use cases |
| Other Applications | 3.7% share | Vaccines, biopolymers, biosurfactants |

Antibiotics still anchor the Microbial Fermentation Technology Market by volume, but the segment's revenue is essentially flat as generic pricing offsets stockpiling demand. Monoclonal antibody production behaves differently: microbial expression handles fragments, bispecific intermediates, and conjugation partners where mammalian systems are uneconomic. That niche is expanding faster than the antibody market as a whole because format diversification favours smaller, faster-expressed constructs.

### By Microorganism Type and Mode of Fermentation

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Bacteria | 43.2% share | E. coli workhorse economics and rapid growth rates |
| Yeast | USD 11.15 Billion | Post-translational capability and food-grade status |
| Fungi / Molds | 15.4% share | Enzyme secretion and mycoprotein production |
| Algae | 8.1% CAGR | Omega-3 lipids and pigment extraction |
| Engineered Synthetic Consortia | 14.0% CAGR | Long-pathway metabolic division of labour |
| Fed-Batch | 51.2% share | Titre optimisation and regulatory familiarity |
| Batch | USD 13.02 Billion | Simplicity for commodity and food applications |
| Continuous | 13.2% CAGR | Capital efficiency and steady-state quality |

Bacterial platforms dominate the Microbial Fermentation Technology Market because doubling times measured in tens of minutes translate directly into asset turnover. Yeast holds the second position and is gaining in food applications where GRAS status shortens approval pathways materially. Fed-batch retains its lead on regulatory inertia as much as performance, since every changed operating mode reopens comparability questions with agencies.

### By Fermenter Capacity and End User

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Mid-Scale (1,000–20,000 L) | 44.7% share | Multi-product flexibility for CDMOs |
| Large-Scale (>20,000 L) | USD 13.50 Billion | Commodity amino acid and antibiotic tonnage |
| Pilot-Scale (<1,000 L) | 13.0% CAGR | Precision fermentation scale-up and process development |
| Bio-Pharmaceutical Companies | 39.0% share | Biologics pipeline and captive capacity strategies |
| Food & Beverage Manufacturers | 13.8% CAGR | Alternative protein and functional ingredient demand |
| Industrial Chemical & Biofuel Producers | USD 6.91 Billion | Substitution mandates and carbon pricing |
| Agricultural & Animal Nutrition | 11.8% share | Biofertiliser and feed enzyme adoption |
| CDMOs, Academic & Research Institutes | 9.3% share | Outsourced development and translational research |

Mid-scale vessels win because they hedge uncertainty. A 10,000-litre suite can serve a commercial niche product or three concurrent clinical programmes, and the Microbial Fermentation Technology Market has learned that flexibility outperforms optimisation when pipelines shift. Biopharmaceutical end users retain the largest share, though food and beverage manufacturers are closing the gap fastest as fermented dairy proteins and mycoprotein secure regulatory clearances in the US, Singapore, and Israel.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 35.4% share | Biologics CDMO expansion, onshoring incentives |
| Europe | USD 11.43 Billion | Bio-based chemicals, enzyme clusters, circular feedstock |
| Asia-Pacific | 13.0% CAGR | API self-sufficiency, alternative proteins, cost arbitrage |
| South America | 5.2% share | Sugarcane-integrated fermentation, agri-inputs |
| Middle East & Africa | USD 1.76 Billion | Health-security localisation, vaccine capacity |
| Total | USD 39.95 Billion | — |

Regional performance in the Microbial Fermentation Technology Market reflects where GMP capacity already sits rather than where demand originates, since fermentation output travels well but capacity does not. Each subsection below discloses a single calibrated metric per country to preserve analytical clarity.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 78.4% of region | Dense CDMO base and federal biomanufacturing awards |
| Canada | USD 1.42 Billion | Montreal and Vancouver biologics clusters |
| Mexico | 9.1% CAGR | Nearshoring of fill-finish and intermediate production |

Federal procurement shapes the North American Microbial Fermentation Technology Market more than private demand does. BARDA's Industrial Base Expansion contracts and the DoD's Distributed Bioindustrial Manufacturing Program together committed over USD 1.1 billion toward domestic fermentation capacity between 2023 and 2025 [[13]](https://defense.gov). Canada's Biomanufacturing and Life Sciences Strategy adds CAD 2.2 billion, much of it flowing to microbial rather than mammalian platforms because of lower unit cost.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 24.6% of region | Industrial enzyme and specialty chemical demand |
| UK | USD 1.94 Billion | Precision fermentation scale-up and CDMO services |
| France | 14.2% of region | France 2030 bioproduction investment plan |
| Italy | USD 0.98 Billion | Generic antibiotic and API manufacturing base |
| Spain | 7.4% of region | Probiotic and food-ingredient fermentation |
| Nordic Countries | 8.2% CAGR | Enzyme innovation and renewable feedstock access |
| Russia | USD 0.61 Billion | Domestic pharmaceutical substitution programs |
| Rest of Europe | 9.8% of region | Ireland and Switzerland contract capacity |

Regulation rather than subsidy drives European volumes. Extended producer responsibility rules and the taxonomy's technical screening criteria make bio-routed chemicals financeable at spreads unavailable elsewhere [[11]](https://ec.europa.eu). Germany's National Bioeconomy Strategy channels roughly EUR 3.6 billion across research and demonstration. At the same time, Denmark's enzyme cluster continues to supply a disproportionate share of global industrial enzyme output relative to national scale.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 34.8% of region | Fermentation-based API and amino acid dominance |
| India | 13.9% CAGR | PLI-backed bulk drug fermentation capacity |
| Japan | USD 1.86 Billion | Green Growth Strategy bio-chemical funding |
| South Korea | 10.6% of region | Biosimilar and CDMO expansion |
| ASEAN | 12.4% CAGR | Palm and cassava feedstock advantage |
| Rest of Asia-Pacific | USD 0.94 Billion | Australian precision fermentation ventures |

Asia-Pacific converts feedstock and labour advantages into the steepest growth curve in the Microbial Fermentation Technology Market. China's MIIT bioeconomy plan targets substantial expansion of synthetic biology output value by 2027, with fermentation named as core infrastructure [[9]](https://miit.gov.cn). India's parallel push has already reversed decades of penicillin-G import dependence, with domestic 6-APA capacity restarting in 2024 after a twenty-year gap.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 56.3% of region | Sugarcane-integrated industrial fermentation bioprocessing |
| Argentina | USD 0.34 Billion | Agricultural biologicals and animal nutrition |
| Rest of South America | 8.7% CAGR | Colombian and Chilean specialty ingredient plants |

Brazil enjoys a structural cost advantage few regions can match, with sugarcane sucrose delivered to fermenter inlets at a fraction of European glucose prices. BNDES credit lines for bioeconomy projects exceeded BRL 4 billion in 2024, targeting biochemical and biofertiliser plants [[18]](https://bndes.gov.br). Constraints are logistical rather than technical: inland plant locations raise export freight costs and cap participation in high-value pharmaceutical supply chains.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27.4% of region | Vision 2030 biotech localisation targets |
| UAE | USD 0.31 Billion | Food-security fermentation and R&D free zones |
| South Africa | 18.6% of region | Vaccine and diagnostic reagent production |
| Egypt | 10.9% CAGR | Generic API and veterinary product manufacturing |
| Rest of MEA | USD 0.42 Billion | Moroccan and Kenyan agri-input ventures |

Health security drives most regional activity. The Africa CDC target of manufacturing 60% of the continent's vaccine requirement domestically by 2040 has attracted development-bank financing toward microbial and viral vector capacity alike [[19]](https://africacdc.org). Saudi Arabia's biotech strategy pairs sovereign capital with technology-transfer conditions, and the UAE's food-security agenda is funding pilot plants for fermented proteins in desert conditions where conventional agriculture cannot compete.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration sits in the moderate band, with an estimated HHI between 850 and 1,050 and a top-five combined share near 40% of the Microbial Fermentation Technology Market. Equipment and consumables are more concentrated than services; a handful of suppliers control the bioreactor and single-use bag installed base, while contract fermentation capacity remains fragmented across dozens of regional operators. Share ranges below are estimates and do not sum precisely.

| Company | Est. Revenue Share Range | Key Offerings for Microbial Fermentation Technology Market | Strategic Positioning |
| --- | --- | --- | --- |
| Thermo Fisher Scientific | ~9–12% | Single-use bioreactors, media, contract fermentation | Breadth leader across hardware and services |
| Sartorius AG | ~8–11% | Benchtop to production bioreactors, PAT instrumentation | Innovation-led, strong in process development |
| Danaher (Cytiva) | ~7–10% | Bioprocess systems, chromatography, automation | Integrated upstream-downstream platform |
| Merck KGaA | ~6–9% | Media, filtration, Mobius single-use systems | Consumables annuity with regulatory depth |
| Lonza Group | ~5–8% | Microbial CDMO capacity, strain platforms | Premium contract manufacturing scale |
| Novonesis | ~4–7% | Industrial enzymes, cultures, biosolutions | Application-led, dominant in enzymes |
| Eppendorf SE | ~3–5% | Parallel bioreactor systems, lab-scale fermenters | Process development specialist |
| ABEC Inc. | ~2–4% | Large custom stainless and single-use vessels | Engineered-to-order large-scale niche |
| Getinge (Applikon) | ~2–4% | Autoclavable and single-use fermenters, controllers | Mid-scale reliability and service network |
| Ginkgo Bioworks | ~1–3% | Strain engineering, foundry services, datasets | Asset-light platform and licensing model |
| Bioengineering AG | ~1–2% | High-containment and specialty fermenters | Containment and custom engineering niche |
| Praj Industries | ~1–2% | Bio-based chemical and biofuel fermentation plants | Emerging-market EPC and feedstock integration |

## Recent News & Developments

## Recent News & Developments

- Lonza (March 2024): Expanded microbial capacity at its Visp campus with additional multi-product suites, targeting fragment and plasmid demand that mammalian lines cannot serve economically [[20]](https://lonza.com)
- US Department of Defense (September 2024): Awarded funding under the Distributed Bioindustrial Manufacturing Program to establish regional fermentation hubs, formalising fermentation as defence-relevant infrastructure [[13]](https://defense.gov)
- Novonesis (January 2024): Completed the Novozymes–Chr. Hansen combination, consolidating enzyme and culture portfolios under a single biosolutions platform [[21]](https://novonesis.com)

- Indian Government (July 2023): Approved additional fermentation-based bulk drug projects under the PLI scheme, restarting domestic penicillin intermediate production after two decades [[8]](https://pharmaceuticals.gov.in)

- European Commission (March 2025): Published the EU Biotech Act roadmap proposing faster permitting for biomanufacturing facilities and a dedicated scale-up fund [[2]](https://ec.europa.eu)

## Frequently Asked Questions

**Q: How should a buyer evaluate contract fermentation partners in the Microbial Fermentation Technology Market?**
A: Prioritise inspection history and comparability track record over nameplate capacity. Request the partner's last three regulatory observation letters and evidence of successful tech transfer at your target scale [12].

**Q: Is vertical integration into strain ownership worth it for mid-sized players in the Microbial Fermentation Technology Market?**
A: Rarely below USD 200 million in annual fermentation revenue. Licensing a validated chassis usually beats building an internal strain group, since regulatory precedent carries more value than incremental titre [23].

**Q: How do procurement teams compare microbial versus mammalian expression on total cost?**
A: Compare grams of released product per campaign-week, not cost per litre. Microbial routes typically win on speed and media cost but lose where complex glycosylation is required [14].

**Q: What integration challenges slow automation retrofits in the Microbial Fermentation Technology Market?**
A: Legacy DCS layers rarely expose the data granularity that model-predictive control needs. Budget for historian replacement and sensor requalification, which frequently exceed the cost of the control software itself [3].

**Q: Which emerging use cases deserve watching before 2030?**
A: Gas fermentation on industrial off-gas and biomanufactured active pharmaceutical intermediates for peptide drugs. Both convert existing waste streams into revenue without requiring new agricultural feedstock [16].

**Q: How does carbon accounting affect fermentation project financing?**
A: Lenders increasingly require verified feedstock chain-of-custody before releasing tranches. Projects lacking certified low-carbon inputs face wider spreads and may be excluded from EU taxonomy-aligned funds entirely [11].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/microbial-fermentation-technology-market-21875*